Symposiums will examine the benefits of half-dose gadolinium-based contrast agent
Guerbet will be unveiling new data on Elucirem (Gadopiclenol), said to be the first half-dose gadolinium-based contrast agent now approved in Great Britain. Delivering high quality images at half the conventional dose, Elucirem is indicated for adults and children aged two years and older for contrast-enhanced MRI of the central nervous system (CNS) and whole […]
Read More